CD40, a member of the tumor necrosis factor receptor ( TNF -R ) family, is a surface receptor best known for its capacity to initiate multifaceted activation signals in normal B cells and dendritic cells ( DCs ). CD40 -related treatment approaches have been considered for the experimental therapy of human leukemias, lymphomas, and multiple myeloma, based on findings that CD40 binding by its natural ligand ( CD40L ), CD154, led to growth modulation of malignant B cells. Recent studies also exploited the selective expression of the CD40 receptor on human epithelial and mesenchymal tumors but not on most normal, nonproliferating epithelial tissues. Ligation of CD40 on human breast, ovarian, cervical, bladder, non small cell lung, and squamous epithelial carcinoma cells was found to produce a direct growth -inhibitory effect through cell cycle blockage and / or apoptotic induction with no overt side effects on their normal counterparts. CD154 treatment also heightened tumor rejection immune responses through DC activation, and by increasing tumor immunogenicity through up -regulation of costimulatory molecule expression and cytokine production of epithelial cancer cells. These immunopotentiating features can produce a ''bystander effect'' through which the CD40 -negative tumor subset is eliminated by activated tumor -reactive cytotoxic T cells. However, the potential risk of systemic inflammation and autoimmune consequences remains a concern for systemic CD154 -based experimental therapy. The promise of CD154 as a tumor therapeutic agent to directly modulate tumor cell growth, and indirectly activate antitumor immune response, may depend on selective and / or restricted CD154 expression within the tumor microenvironment. This may be achieved by inoculating cancer vaccines of autologous cancer cells that have been transduced ex vivo with CD154, as documented by recently clinical trials. This review summarizes recent findings on CD154 recombinant protein -and gene therapy -based tumor treatment approaches, and examines our understanding of the multifaceted molecular mechanisms of CD154 -CD40 interactions.
CD40 expression and function in human cells
CD40 was independently identified as a surface marker on bladder carcinomas and on B cells in 1985. 1 Early functional analysis has established a critical role for this cell surface receptor for B -cell activation in thymus -dependent humoral responses. The natural ligand for CD40 is a Type II, 39 -kDa membrane glycoprotein known variously as CD40L, TRAP, and T-BAM. This molecule was defined and isolated in activated T cells in 1992 by CD40 -Fc fusion protein and expression cloning techniques, 2 and was subsequently designated as CD154.
CD40 and CD154 expression has since been established in a wide array of normal hematopoietic and nonhematopoietic cell types. CD40 is constitutively expressed on cells with high proliferative potential, including hematopoietic progenitors, epithelial and endothelial cells, and all antigenpresenting cells [dendritic cells (DCs ), activated monocytes, activated B lymphocytes, follicular DCs ]. 3 This surface receptor is also found on eosinophils and CD8 + T cells and fibroblasts of synovial membrane and dermal origins. 4 Within the thymus, CD40 is expressed on both cortical and medullary epithelia and on thymus interdigiting cells. 5 By comparison, CD154 is expressed transiently on activated leukocytes, including mature CD4 + T cells, CD8 + T-cell subsets, and g T cells; and mast cells, eosinophils, and IL-2 activated NK cells. 6 CD154 also has been detected in purified monocytes, activated B cells, epithelial and vascular endothelial cells, smooth muscle cells, and DCs, although the in vivo relevance of CD154 expression in these cell types has not been clearly defined. 3 The CD40 and CD154 receptor ligand pair is classified correspondingly as members of the tumor necrosis factor receptor (TNF -R ) and TNF family of molecules, respectively.
The multifaceted nature of CD40 signaling is exemplified by its diverse physiologic effects in normal B cells. CD40 emerges early on CD34 + B -cell precursors in the bone marrow before immunoglobulin gene rearrangement and is expressed on B cells until their terminal differentiation into plasma cells. 7 CD40 ligation led to largely positive growth outcomes for resting B cells, but inhibited the growth and immunoglobulin production of activated B cells. 8 -12 The differentiative path of the antigen -activated B cell is ultimately determined by the extent of CD40 activation. Abbreviated CD154 exposure skewed the germinal center B cell to terminally differentiate into a plasma cell, whereas prolonged CD154 exposure generated CD40 + memory B cells. 13, 14 Patients with CD154 mutation/dysfunction suffer from X -linked hyper-IgM immunodeficiency syndrome or common variable hypogammaglobulinemia, 15 manifesting as an inability to produce IgG, IgA, and IgE immunoglobulin isotypes that are needed for an effective, secondary humoral response. Interestingly, these patients suffer from recurrent pyogenic infections as well as a higher risk of developing lymphomas and gastrointestinal cancers. 16, 17 Likewise, the initiation and maintenance of cell -mediated immune responses interaction are critically dependent on the interaction of CD154 -expressing, activated T cells with CD40 + DCs. 3, 18 CD154 produces a prosurvival signal in the DC, and up -regulates costimulatory/accessory molecule expression ( MHC class II, CD58, CD80 / CD86 ) that enhances antigen presentation by the CD40 + DC. This interaction in turn ''primes'' CD154 + helper and cytotoxic T cells by up -regulating their interleukin ( IL) -2 receptor expression, and leads to the expansion of both class II -and class I -dependent tumor-reactive T-cell pools. 19 -21 Following CD154 activation, the antigen -presenting DCs further promoted cell -mediated immunity by an increased production of TNFa, macrophage inflammatory protein (MIP )-1a, IL-8, IL-12, 22, 23 and the recently identified signaling lymphocytic activation molecule ( SLAM ) that coordinately activated neighboring DCs and T cells. 24 Another aspect of CD40 -CD154 immune regulation is the enhanced cytotoxic capability of IL -2 activated, CD154 -expressing NK cells 25 after engaging CD40 + target cells. For cells of the reticuloendothelial system, CD40 activation is critical for proinflammatory responses. CD154 up-regulated adhesion molecule ( E -selectin, VCAM -1 / CD54 ) expression 18, 26 and triggered proinflammatory cytokine secretion ( IL-1, IL -6, IL -12, interferon/ IFN, TNFa) by monocytes, fibroblasts, keratinocytes, DCs, smooth muscle cells, and endothelial cells.
18 CD154 binding also modulated the transcription of chemokines and their receptors on macrophages and DCs. CD154 expression on lung and skin mast cells and activated blood basophils may enable these cells to induce IgE secretion by B cells in the presence of IL -4. 6 Studies with CD154 -blocking reagents and CD40 or CD154 knockouts demonstrated the contribution of aberrant CD40 activation to chronic inflammatory diseases including rheumatoid arthritis, 3, 27, 28 atherosclerosis, 29, 30 neurodegenerative disorders, graft -versus -host disease, and allograft rejection. 31, 32 Recently, increased CD154 -CD40 expression was correlated with elevated cyclooxygenase-2 and nitric oxide synthase at chronic inflammation sites. 18, 30 CD154 also induced and activated metalloproteinases that, through matrix degradation, may be instrumental in tissue destruction observed in rheumatoid arthritis or atherosclerosis. 3 An increased CD154 expression on T cells of patients with multiple sclerosis, 33 systemic lupus erythematosus, 34 and myasthenia gravis 35 may contribute to disease pathogenesis by virtue of their proinflammatory features. Conversely, chronic autoimmune inflammatory process and alloimmune responses can be abrogated by neutralizing CD40 -CD40 ligand interactions, suggesting that this ligand -receptor pair engenders a central regulatory role in determining the activation versus tolerance outcome of T-dependent immune responses (Table 1 ) . Epithelial CD40 expression is primarily restricted to selfrenewing stem cells residing in the basal layer, such as basal / proliferative layer of nasopharyngeal, tonsillar, and ectocervical epithelium. CD40 binding has produced a uniform cytostatic /growth -inhibitory outcome 17 and phenotypic alterations that may influence the local inflammatory response. 36 It has been speculated that activation of CD40, Fas, or the b1 -integrin receptor, all of which are localized on 
17
CD40 expression on malignant cells generally mirrors their normal, proliferating counterparts, and has been detected on B -cell malignancies, melanomas, and a variety of carcinoma cell types. 17, 38, 39 Based on the growth -and immune -regulatory features of CD154 -CD40 interaction in normal cells, agonistic anti -CD40 monoclonal antibodies ( mAbs ), recombinant CD154, or CD154 gene transfer agents have been considered to promote corresponding direct and indirect tumor growth -inhibitory outcomes. These findings are summarized in the following sections, which also examine the findings of recent Phase I /II cancer experimental therapy trials with recombinant CD154 and CD154 gene transfer, and our current understanding of molecular pathways that mediate the diverse cellular outcomes following CD40 ligation.
Direct growth inhibition of cancers
Much like the diverse regulatory effects of CD40 on normal cells, CD154 produced a wide range of growth -regulatory effects on CD40 -expressing tumor cells (Table 2 ). In Hodgkin's disease and low -grade B -cell malignancies such as follicular lymphomas, 40, 41 hairy cell leukemia, 42 and B chronic lymphocytic leukemias (B -CLL 43 ), CD40 activation contributed to tumor survival and resistance to chemotherapy. 9, 44 CD40 binding triggered the growth of human immunodeficiency virus ( HIV ) -related lymphomas, possibly through increased vascularization and activation of nuclear factor kappa of B cells ( NF -kB ), which in turn stimulated HIV replication. 45 Recent preliminary findings of Aldinucci et al 46 identified CD40 expression in 84% of patients with acute myelomonocytic leukemia. Exposure to soluble CD40 ligand led to dose -dependent proliferation and clonogenic colony formation of the leukemia blasts in vitro.
In contrast, CD40 cross -linking induced cell cycle arrest in murine ( BCL1 ) and human ( Daudi ) B lymphoma cells, which was critical for the induction and maintenance of tumor dormancy. 47 For posttransplant, Epstein-Barr virus ( EBV )-positive high -grade aggressive lymphomas, CD40 binding led to growth inhibition through the induction of apoptosis. 48 Growth arrest, up-regulation of Fas, and increased apoptosis 16, 47 were similarly observed in vitro following CD40 binding of non -HIV, high -grade malignancies such as Burkitt's lymphoma. 44 We and others showed that human multiple myeloma cells also expressed CD40, 49, 50 and underwent growth arrest upon treatment with soluble, recombinant CD154. 10, 17, 50, 51 A bimodal growthregulatory process for myeloma cells has been suggested by Teoh et al, 52 where CD40 ligation activated myeloma cells in the initial phase followed by induction of apoptosis, with a correspondingly distinct compliment of gene sets that is related to cell cycle progression, or apoptosis that is significantly enhanced by Apo -1 /Fas (CD95 ) ligation.
53
CD40 ligation appears to play a growth -inhibitory / prodifferentiative role for normal as well as malignant epithelial cells. In the oral basal epithelium, >80% of total cells coexpressed CD40 and CD154. A loss of CD154 expression and maintained expression of CD40 may contribute to epithelial tumorigenesis, as observed recently in squamous cell carcinoma. 54 -56 Consistent with this hypothesis, patients with X -linked hyper-IgM syndrome also suffered from an increased incidence of developing carcinomas of the liver, pancreas, and biliary tree. 16, 17 The loss of CD154 -dependent epithelial cell growth regulation, or uncontrolled chronic infection and inflammation, has been suggested by Young et al 17 to contribute to increased tumor susceptibility.
CD40 expression has been documented in nasopharyngeal, colorectal, bladder, ovarian, liver, and breast carcinomas, whereas CD154 was not endogenously expressed, or expressed at very low levels. Strong expression of CD40 in the tumor vasculature of renal 57 and breast 58 carcinomas suggests a potential role of this receptor in tumor angiogenesis. In a concurrent evaluation of CD40 and CD154 expression, we found that CD40 was expressed on all primary breast tumor histologic subtypes, including infiltrating ductal and lobular carcinomas, and carcinomas in situ. " clonogenicity, resistance to chemotherapy [ 9, 44 ] ( " ) Increased; ( # ) decreased. NHL: non -Hodgkin's lymphoma; CLL: chronic lymphocytic leukemia.
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Although focal areas of the tumor populations also expressed CD154, this molecule was detected primarily within the cancer cell cytoplasm with rare membrane staining, suggesting that expression of the membrane -bound CD154 may be uncommon, or occurs transiently (and hence escapes detection ). Restricted endogenous CD154 expression may limit its impact towards regulating disease progression. 58 Further, CD154 was rarely expressed among tumorinfiltrating lymphocytes (TILs) in the majority of breast cancer cases tested, suggesting that TILs in established breast cancers may lack the ability to down -regulate tumor cell growth through CD40L -CD40 interaction.
58
A direct growth -inhibitory effect through CD40 binding of epithelial cancers was first demonstrated by Hess and Engelmann, 38 who showed that CD154 transgene expression in HeLa cervical carcinoma cells dramatically reduced growth rate in vitro. This CD40 -mediated growth -inhibitory effect did not appear to be mediated by apoptosis in studies of bladder, ovarian, and skin carcinomas, and was additive with the proapoptotic activities of cytotoxic cisplatin and other biologic response modifiers including TNFa, Fas ligation, and ceramide. 54 Recently, human non small cell lung carcinomas were also found to express CD40. CD154 treatment caused dose -dependent, reversible cell cycle Sphase blockage in the tumor subset that expressed a high level of CD40 59 -a mechanism that was similar to its cell cycle blockade of cisplatin-resistant ovarian cancer cells. 17 For breast and squamous carcinoma lines and SV40 -transformed keratinocytes, apoptotic induction appeared to play a critical role in CD40 -dependent growth -inhibitory effect (Table 2 54 ). CD154 also inhibited melanoma cell proliferation in vitro through apoptotic induction, 60 enhanced tumor-specific lymphocyte-mediated tumor cytotoxicity, and stimulated the production of immune-activating cytokines by melanoma cells that included IL -6, IL -8, and TNFa.
Studies with human B lymphoma xenografts in severe combined immunodeficiency (SCID ) mice validated the in vivo tumor-inhibitory properties of CD154 in the absence of T-and B -cell activation. 16, 61 We and others observed a similar antitumorigenic effect on CD40 + human breast cancer cell line xenografts in SCID mice, 58, 62 for which different constructs of soluble CD154 produced a uniform growth -inhibitory effect. Agents that were evaluated included gp39, a CD40L -CD8 recombinant molecule, 63 the trimeric human CD40 ligand /leucine zipper fusion protein huCD40LT, 64 and the recombinant rhsCD40L of similar construct without a leucine zipper. 65 Cotreatment with the CD154 -blocking antibody LL48 abrogated this antitumor effect in vitro and in vivo, confirming CD40 dependence of this phenomenon. Conversely, CD154 was ineffective in altering CD40
À breast cancer cell growth. These in vivo findings illustrated the direct, in vivo immunotherapeutic effect of CD154 on CD40 + carcinomas. However, these SCID -hu xenograft studies cannot exclude the potential contribution of tumor-infiltrating monocyte /macrophages, which may be activated by CD40 ligation and may produce antitumor cytokines and /or activated NK cells. 66, 67 In a recent study with human ovarian cancer cell line and primary tumor xenografts in SCID mice, rhuCD40L treatment demonstrated a significant antitumor effect that was additive with cisplatin and unaffected by cotreatment with antiasialo GM -1 that blocked NK activity. 68 These findings confirmed the direct growth -inhibitory effect of rhuCD40L on epithelial ovarian tumors.
Like the normal epithelium, 17 CD40 expression on breast carcinoma cells can be up-regulated by IFNg treatment, which was shown to synergize with an agonistic anti -CD40 mAb in inhibiting the growth of SCID -hu breast cancer cell line xenografts. 62 Wingett et al 69 showed that IFNg preactivation was required for a significant, CD40 -dependent antitumor response in vivo. By contrast, we 58 and others 62 observed that IFNg production was not critical for CD154 -induced tumor growth inhibition, although an enhancing effect by this and other cytokines cannot be excluded.
62,70
The findings described above indicate that CD154 can regulate cell growth in positive and negative directions: CD40 signaling rescues normal B cells, monocytes, DCs, and fibroblasts from cell death, but promotes apoptosis in transformed cells of mesenchymal and epithelial origin as well as neuronal cells and hepatocytes. The triggering of other receptors ( p55 and p70 TNF -receptors, CD30, CD19 ) may similarly activate normal cells while inhibiting the growth of transformed cells. This phenomenon has been termed ''activation -induced cell death'' (AICD ) 71 in the context of immune cell interactions, where the circumstance of cell activation versus inhibition appeared to depend on the coordinate activation of other surface molecules (such as the antigen receptor ) and physiologic state of the receptorexpressing cell (proliferation versus quiescence, intracellular reducing /oxidating state balance ). 72 -75 As members of the TNF -R superfamily, CD40, CD30, and the TNF -Rs share the common feature of lacking a cytoplasmic domain with intrinsic kinase or other well-defined signal transduction capacity. Rather, CD154 binding induced CD40 homotrimerization without altering its conformation. 65,76 -78 This event induces oligomerization of members of the TRAF (TNF -R associated factor ) family of signal transducers that bind to two conserved, complementary CD40 cytoplasmic domains ( TRAF domains 78, 79 ). Of the six TRAF members identified to date (TRAF1-6 ), TRAF3 is most prominently associated with CD40 signaling, and competes with TRAF1 and TRAF2 for a TRAF domain distal to the plasma membrane. 79, 80 TRAF5 may also associate at this domain through interaction with the RING finger domain of TRAF2 and TRAF3. 81 A fifth member, TRAF6, associates with a second CD40 TRAF domain proximal to the plasma membrane and may serve to modulate TRAF1, TRAF2, TRAF3, or TRAF5 binding outcome. 77, 79 The homo -and heterooligomerization of individual TRAFs in turn activate unique as well as overlapping pathways whose affiliation is cell type -and activational state -dependent. These include two subfamilies of the stress -activated protein kinases, i.e., JNK (c -jun N -terminal kinase, also known as stress -activated protein kinase or SAPK ) and the p38 mitogen -activated protein kinase (MAPK ); 82 the transcription factors NFkB, activating protein -1 ( AP -1 ), nuclear factor for activated T cells ( NFAT ), signal transducer and activator of transcription ( STAT ) 3 and 6; 82 and other kinases including apoptosis signal-regulating kinase -1 and the germinal center kinaseCancer Gene Therapy CD154 treatment of human cancer AW Tong and MJ Stone related kinase. 83 TRAF1, TRAF2, and TRAF5 also contained specific DNA binding motifs and can directly regulate DNA transcription 84, 85 of CD40 -responsive genes including members of the TNF (LTa and CD70 ) and TNF -R family ( TNF -R1 and TNF -R2, CD40 ), 82 cell cycle regulatory proteins Cdk4 and Cdk6, 85 antiapoptotic elements (cIAP, inhibitor of apoptosis, and Bcl -x L ), and the proapoptotic element DR3, which mediates cell death as well as upregulates CD95 /Fas expression. 82 It is of interest to note that much of the CD40 -mediated phenotypic alterations in B cells and epithelial tumors can be mimicked through activation of the EBV-1 encoded latent membrane protein, LMP -1. This was primarily attributed to LMP -1's capacity to induce binding and oligomerization of TRAF1, TRAF2, and TRAF3, and to activate downstream NFkB, AP1 transcriptional factors, and the c-JNK cascade. 17, 54, 55 Thus, unique TRAF subsets are considered to be the critical link that converts CD40 -initated signals to multifaceted physiologic outcomes. For the normal B cell, TRAF2, TRAF5, or TRAF6 recruitment activated the c -JNK pathway; 86 the extracellularly regulated kinase mitogen -activated protein kinase ( ERK -MAP kinase 87 ) mobilized cytoplasmic NFkB to bind multiple gene -regulatory regions ( kB sites ) in the nucleus and resulted in up -regulated transcription of cytokine (IL -6), adhesion molecule (CD54 ), and antiapoptotic proteins such as cIAP1, cIAP2, 88 and Bcl -x L , and A1. 87 The up -regulation of antiapoptotic proteins enhanced the prosurvival effects of CD40 signaling, whereas coengagement of the membrane Ig receptor with CD40 limited Fas expression and led to TRAF3 -mediated feedback inhibition of CD40 -dependent activation events. 84, 89, 90 For T cells, CD40 binding led to the upregulation of TRAF1, which served an antiapoptotic role much like its involvement in inhibiting antigen -induced cell death in CD8 + T cells. 82 CD40 ligation increased c -jun ( and not c -fos ) mRNA, leading to SAPK activation 45 without affecting ERK1 and ERK2. 45 By comparison, CD40 ligation strongly up -regulated TRAF1 mRNA in human monocytes, and TRAF1 and TRAF5 in the monocytic line THP1. Both normal monocytes and THP1 cells exhibited rapid and transient activation of ERK1 /2, their upstream activator, MAPK kinase ( MEK ) 1 and 2, as well as the downstream substrate c -Myc. 91 Thus, markedly different downstream signaling processes may account for the diverse physiologic outcomes that result from CD40 activation in normal B, T, and monocytic cells.
Currently, the molecular mechanisms of CD40 -mediated cancer growth regulation remain poorly defined. A significant proportion of non -Hodgkin's lymphomas ( NHLs ) and B -CLL overexpressed TRAF1, whose expression was highly restricted in normal peripheral blood lymphocytes. 83 Differences in the expression of combinations of TRAF family proteins may impact their capacity to heterooligomerize and recruit proapoptotic proteins to TNF -R members. 83, 92 We and others showed that CD154 -induced growth inhibition of human myeloma cells involved the up -regulation of TRAF4 and TRAF6 and the induction of apoptosis. 51, 93 For CD40 cross -linking on carcinoma cells, the most common molecular outcomes were NFkB activation and engagement of the c-JNK cascade, leading to increased ICAM -1 expression and IL -6 and IL-8 production. 54, 55, 95 Studies with dominant negative TRAF mutants show that TRAF3 was required for CD40 -mediated growth inhibition of various carcinomas, 54 whereas TRAF1 and TRAF3 were required for increased transcription of ICAM -1 and IL -6 in these cell types. 54, 55 One potential role of TRAF3 may be the modulation of NFkB -dependent pathways. 54 However, blockage as well as activation of NFkB and the JNK cascade has been reported to be the underlying mechanism of CD40 -mediated growth inhibition in carcinoma cells. 17, 54, 55, 62 CD154 -induced breast cancer cell growth inhibition correspondingly activated endogenous apoptotic pathways, as shown by us and others. 58, 69, 75 Whereas CD40 lacks the death domain and its link to ICE caspase activation, apoptosis may nevertheless be initiated through TRAF association (which in turn recruits death domain containing molecules such as TRADD ), through transactivation of other TNF -R members that expressed the death domain ( such as TNF -R1 and Fas ), 69, 94, 95 or by collaterally activating caspases and the JNK pathway. 96 These events depended on the integrity of the CD40 membrane proximal domain but, interestingly, not its TRAF-interacting motif. 78 An increased production of cancer death -inducing cytokines such as TNFa, IL -6, IL-8, and granulocyte -macrophage colony -stimulating factor (GM -CSF ), 97 and /or corresponding caspase activation/ s 94, 98, 99 may also contribute to CD40 -dependent tumor growth inhibition.
In our study of human breast cancer xenografts, we detected significantly elevated proapoptotic bax and bak mRNA without alteration of bcl -2 in T47D and BT-20 cells during soluble CD154 -induced growth inhibition, 51 whereas cotreatment with a CD40L -blocking antibody abrogated apoptotic induction and the up -regulation of Bax. Thus, an altered balance of the bcl -2 family likely contributed to CD40 -mediated growth inhibition, which may also involve the endogenous production of cytotoxic cytokines and autocrine / paracrine induction of cell death. 95 
Antitumor immune response activation
Both experimental and clinical observations indicate that an inadequate antitumor immune response may facilitate tumor progression. A deficient immune response may stem from the lack of tumor immunogenicity ( decreased/ altered MHC class I expression, decreased and /or heterogeneity of tumor antigen, or lack of adhesion or accessory / costimulatory molecules ), immune unresponsiveness (e.g., tolerance, anergy, immune ignorance, clonal deletion ), the presence of immunosuppressive proteins ( e.g., transforming growth factor-b, Fas ligand ), or changes in the expression of T-cell signal transduction molecules (reviewed in Ref. [100 ] ). CD40 ligation has been shown to stimulate host antitumor immune response in numerous tumor models. CD40 knockout mice had significantly increased incidence of spontaneously arising tumors and, unlike mice with a wild -type genetic background, could not mount a protective specific immune response against subsequent tumor challenge following sensitization with GM -CSF -transfected, syngeneic
Cancer Gene Therapy CD154 treatment of human cancer AW Tong and MJ Stone B16 melanoma tumor. 101 Intratumoral administration of agonistic anti -CD40 mAb produced a strong, systemic, tumor-specific cytotoxic T-cell response that was sufficient to eradicate preexisting CD40 + murine tumors. 102 Conversely, CD154 gene transfer slowed the growth of MCA -1 or TS /A murine tumor lines. 103 Coimmunization with an anti -CD40 cross -linking antibody and the cRL1 tumor peptide induced cytotoxic response and prolonged survival of tumor-bearing mice. 104 Parental murine bladder cancer MB -49 xenografts were eradicated in 94% of syngeneic hosts following injection of CD154 -transduced tumor cells, which protected against subsequent parental, untransfected tumor challenge. 105 Immunosensitization contributed significantly to this antitumor approach, as evidenced by the rapid infiltration of large numbers of CD4 + and CD8 + T cells in the CD154 -expressing tumor anlage.
The immunostimulatory effects of CD154 correlated with its capacity to activate DCs in a number of murine tumor models.
20,106 -109 CD40 binding produced a prosurvival outcome in DCs, attained in part through the activation of the antiapoptotic serpin serine protease inhibitor 6 in tumorinfiltrating DCs. 110, 111 Following in vitro maturation treatments of GM -CSF and IL -4, CD154 ( or TNF ) exposure was required to optimize the antigen -presenting functions of monocyte -derived DCs. 112, 113 Recombinant CD154 treatment produced a mature DC morphology, up -regulated expression of adhesion and costimulatory molecules ( ICAM -1, CD83, CD80 / 86), and heightened secretion of proinflammatory cytokines (IL -12, IL -6, TNFa) and chemokines (IL -8, MIP -1a ). 113 Activation by CD154 in the presence of proinflammatory cytokines or IFNg was necessary for the ''cross-priming'' function of DCs, by which ingested tumor apoptotic body -derived antigens were presented to T cells in the context of HLA class I, leading to the activation of tumor-specific cytotoxic T effector cells.
107,114 -117 When exposed to proinflammatory T H 1 antigens, DCs up-regulated CD40 expression and acquired an increased ability to produce IL -12 in response to CD40 engagement by CD154 + activated T cells. 118 IL-12 production by DCs was pivotal for initiating a T H 1 response. 119 In addition, CD40 -activated, monocyte -derived human DCs played a critical role for skewing the CD4 + T cell from a T H 2 phenotype to an IFNg -producing T H 1 phenotype. 120 An equally significant role of CD40 binding has also been identified for initiating an immune response against T H 2 infectious antigens. 118, 121 In certain experimental models, CD154 expression on NK cells may contribute to an antitumor outcome. Spontaneous tumor regression of subcutaneously engrafted rat AK -5 histocytomas was mediated by activated CD8 + CD3 À NK cells. The interaction of transplanted, CD40 -expressing tumor cells elevated CD154 expression of NK cells, and ultimately activated NK cytotoxicity in part through NFkB mobilization. These findings are consistent with the hypothesis that CD154 expression by effector cells is regulated by IL -12 and IFNg, and an up -regulated CD154 in turn could modulate NKmediated cytotoxic response. 122 Further, CD154 binding enhanced the antigen -presenting capability of cancer cells through an up -regulated expression of endogenous tumor peptide and T-cell costimulatory molecules. Ranheim and Kipps 123 first demonstrated that activated, CD154 -expressing human T cells induced normal and leukemic B cells to express B7 and significantly higher levels of CD54. Follicular lymphomas were highly inefficient at presenting alloantigens despite their high level of MHC expression. For this cell type, CD40 binding upregulated B7 -1 /B7 -2 ( CD80 / 86), ICAM -1, and LFA -4, which may stabilize tumor cell contact with activated T cells through interaction with their respective ligands CD28, LFA -1, and CD2. For Burkitt's lymphomas, CD40 activation resulted in the up -regulation of MHC class I molecules, peptide transporter for antigen presentation ( TAP ) expression, and endogenous antigen processing functions, which contributed to a more efficient recognition of lymphoma by specific cytotoxic T lymphocytes. CD40 binding also played a critical role in enhancing the antigen -presenting function of acute myelogenous leukemia (AML ) cells and their maturation into leukemia DCs. 124 -126 AML cells that retained characteristic cytogenetic markers had up-regulated CD80, CD83, CD86 expression, and an increased capacity to stimulate leukemia -specific or allogeneic T-cell cytolytic activity 124 following in vitro treatment with CD40L, GM -CSF, and IL -4, 125 or CD40L and ATRA ( all -trans retinoic acid ). 125 Likewise, CD40 cross -linking by recombinant CD154 produced a 6-fold increase in surface MHC class I, Fas, and intracellular adhesion molecule in non small cell carcinomas that expressed a high level of CD40. 59 In addition to producing an altered surface phenotype, CD40 binding also increased immunostimulatory cytokine production in certain tumors. CD40 binding of Hodgkin's lymphoma cells increased the secretion of IL -8, the T-cellactivating pleiotropic cytokine IL -6, and tumor-regulating TNF, which in concert may enhance antitumor immune response particularly through T-cell attraction and activation. In addition to significantly increased immunogenicity, CD40 ligation of patient acute lymphoblastic leukemia cells also induced the secretion of the CC chemokines macrophage -derived chemokine ( MDC ) and thymus and activation -regulated chemokine ( TARC ) that serve as potent chemoattractants for the transendothelial migration of autologous CCR4 + antileukemia T cells. 127 Thus, CD40 stimulation may enhance the effectiveness of the host's antitumor immune response afferently by improving antigen presentation, and efferently by enhancing cytotoxic activity and cytokine secretion. The critical role of collateral activation of APC and T cells through CD154 -CD40 interaction is supported by recent gene transfer studies as described in the following section.
Induction of antitumor immunity by CD154 -transfected cells
Following CD154 transfection, murine lymphoblastic leukemia A20 cells had up-regulated expression of B7.1, and MHC class I and II molecules. Inoculation of CD154 -transfected cells into a syngeneic host produced a highly effective tumor rejection response that also eliminated preexisting A20 tumor cells at a distant site. This antitumor response was mediated by CD4 + and CD8 + T cells and NK
Cancer Gene Therapy CD154 treatment of human cancer AW Tong and MJ Stone cells. 128 Cancer cells from patients with primary follicular lymphoma 129 and B -CLL 130 also had increased expression of immune costimulatory molecules following in vitro transfection with a CD154 adenovector and a helper virusfree CD154 -herpes simplex virus amplicon, respectively. Both CD154 transgene -expressing lymphoma and CLL cells have an enhanced capacity to stimulate T-cell proliferation. 129, 130 Human NHL or B -CLL cells cotransfected with adenovectors carrying CD154 or IL -2 produced an additive T-cell activation response and sensitized autologous T cells that can recognize parental, untransfected B -CLL cells. 131, 132 The toxicity and immunostimulatory efficacy of a CD40L and IL-2 expressing B -CLL tumor vaccine is currently being examined. 133 Murine J558 myeloma cells expressing the CD154 transgene activated DCs with enhanced B7 -1 and ICAM -1 expression, and led to T-cell -mediated protective immunity against the wildtype parental cell line. 134 Similarly, human myeloma cells underwent apoptosis upon introduction of CD154 by an adenovector, which also induced maturation of bystander DCs that in turn activated tumor-reactive T lymphocytes. 135 Thus, CD154 transgenic expression on multiple myeloma cells can exert a dual effect of direct growth modulation 50, 51, 135 as well as stimulating tumor-reactive cytotoxic T lymphocyte activity. 136 In murine syngeneic solid tumor models, ADV-CD154 injected directly into established subcutaneous B16 melanoma, MCA -1 sarcoma, or CT26 colon carcinoma produced sustained tumor regression in the majority of tumor-carrying mice. 95, 103, 109 Systemic immunosensitization can be demonstrated by virtue of immune rejection of contralaterally implanted, nontransfected tumors. Similarly, CD154 gene transfer elicited a tumor-specific cytolytic T lymphocyte response that suppressed the growth of established, weakly immunogenic Lewis lung carcinoma in the presence of IFNg. 136 The CD154 -activated T-cell response can be transferred to naïve recipients to protect against subsequent tumor challenge. 106, 136 Preestablished murine K1735 melanoma, CMT93 colon, 109 MB -49 bladder, 105 and rat MCA -RH7777 hepatocellular carcinoma 137 also underwent sustained regression following intratumoral injection of CD154 -transfected cells.
According to Loskog et al 105 and Nakajima et al,
138
CD154 transgene expression on tumor cells promoted local and systemic antitumor immunity by up -regulating B -7 expression on DCs and their secretion of IL -12 that was accompanied by influx of significant numbers of CD4 + , CD8 + T cells and NK cells at the site of CD154 + tumor cell inoculation. The recipients of CD154 transgene -expressing tumor cells withstood subsequent challenge of lethal doses of untransfected tumor cells. 139 Indeed, this immunosensitizing effect of CD154 transgene expression can be reproduced with the intratumoral injection of CD154 -transfected DCs. The CD154 -transfected DC most likely underwent self -and reciprocal CD40 activation and presented tumor antigens to naive CD8 + T cells. The intratumorally introduced CD154 transgene can subsequently be detected in the spleen of the tumor host, which was consistent with the conventional expectation of activated DC migrating into peripheral lymphoid organs to initiate the immune-relevant process, producing tumor-specific T cells that were effective in inducing regression of the contralateral tumor. 112 Recently, Urashima et al 108 utilized a Salmonella typhimurium vaccine to deliver the CD154 transgene by the oral route. The live, but attenuated, bacterium penetrated the epithelial M cells to reach the Peyer's patches, and activated local antigen -presenting cells following mucosal bacterial uptake mechanisms. This auxotropic S. typhimurium strain was nonvirulent because it required metabolites not available in vertebrate tissues for its survival. This oral gene transfer approach with CD154 resulted in a high degree of protection against the development of a CD40 + B cell lymphoma (BCL ) as defined by significantly prolonged survival for tumor-bearing mice, and the recruitment of Fas ligand -positive TILs. These findings suggest that oral delivery of CD154 by attenuated S. typhimurium may serve as an effective and safe mucosal immune -activating approach against BCL.
CD154 -based cancer clinical trials
The efficacy of agonistic CD40 -reactive mAb for clinical applications is limited by pharmacokinetic constraints particularly for the targeting solid cancers and the likelihood of eliciting human antimouse neutralizing antibodies ( HAMA ) that limit its therapeutic effectiveness. In addition, sustained systemic treatment with either CD40 -agonistic mAb or the recombinant CD154 protein engenders potential toxicity from proinflammatory cytokine production by CD40 -activated endothelial cells. 18, 26, 30 Interestingly, this concern was not realized in 32 patients with advanced solid tumors or intermediate or high -grade NHL, who were treated subcutaneously with recombinant CD154 (rhuCD40L ) for 5 days in a recent Phase I clinical trial (Table 3 140 ). The maximum tolerated dose was found to be 0.1 mg /kg /day, with a serum half -life of 25 hours. Grade 3 or 4 transaminase elevations occurred in 14%, 28%, and 57% of patients treated at 0.05, 0.10, and 0.15 mg /kg /day, respectively. After a single treatment course, 12 patients ( 38% ) had stable disease, which was maintained in four patients through three additional courses of treatment. Two patients ( 6% ) demonstrated a clinical response, including one with Stage IV progressive laryngeal cancer who attained a partial response after one course of 0.1 mg / kg/ day rhuCD40L. His remission was sustained for 11 additional courses over 12 months, and was then taken off therapy with no further treatment. Three months later, the patient was found to have complete remission and remained biopsy -proven free of disease for a total of 24 months since entered into trial. 140 Of the nine NHL patients entered into trial, partial response was attained with one patient with progressive large cell immunoblastic T-cell lymphoma after one course of rhuCD40L, as evidenced by regression of skin lesions and reduced lymphadenopathy. 141 However, the patient did not respond to subsequent rhuCD40L treatments. RhuCD40L did not produce durable clinical responses in the remaining eight B -cell NHL patients. These findings indicate that therapeutic doses of recombinant CD154 may produce a clinically beneficial effect in selected human cancers, while causing only transient hepatotoxicity.
Recent studies have compared the efficacy of the recombinant CD154 protein and CD154 gene transfer in stimulating host antitumor immune responses. 142 Treatment with recombinant CD154 or CD154 transgene -expressing tumor cells was equally effective in inducing the maturation of tumor antigen pulsed monocytic DCs. However, CD154 transgene -expressing tumor cells may have a more profound immunopotentiating effect by virtue of their capacity to trigger costimulatory molecule (CD80 and CD86 ) expression as well as release of the T H 1 -activating cytokine IL -12. 142 Kedl et al 143 recently showed that CD40 coactivation with concomitant tumor antigen presentation can produce a long -term -albeit variable -antitumor outcome, whereas CD40 ligation in the absence of tumor antigen actually led to deletion of tumor-antigen -specific T cells. Batrla et al 144 showed that endogenous CD154 expression density of activated T cells was down -regulated following interaction with CD40 + carcinoma cells, suggesting that CD40 expression may actually serve as counteroffense by tumor cells to suppress T-cell activation. Thus, the copresentation of CD154 and tumor-associated antigen through CD154 gene transfer into tumor cells would be preferred for ''tumor-specific'' vaccination. The use of ex vivo CD154 -transduced tumor cells serves to limit CD154 transgene expression to the tumor microenvironment in view of their homing properties, 145 thereby minimizing potential toxicity that may result from uncontrolled, systemic CD154 transgene expression as seen in murine models. CD40L knockout mice developed T lymphoproliferative disorders after autologous transplantation of CD154 -transfected bone marrow or thymic cells. 146 Lethally irradiated normal mice developed Crohn's disease -like autoimmune bowel disease following CD154 transgene expression in the murine thymus. 147 The clinical applicability of ex vivo CD154 -transduced tumor has been examined in a number of recent trials ( Table 3 ). According to Kato et al, 148 CD154 -transfected patient CLL cells induced an increased level of immune accessory molecules in transfected cells as well as neighboring CD40
+ noninfected leukemia cells. In vitro exposure to CD154 transgene expressing leukemia cells led to increased serum IFNg and clonal expansion of cytotoxic T lymphocytes that reacted specifically with autologous, nonmodified leukemia cells. 148 Based on the premise that CD154 -expressing tumor cells can provide an immune-stimulatory effect, which in turn results in altered tumor growth, CLL patients were infused with CD154 -transfected autologous leukemia cells in a Phase I dose escalation study. 149 Eleven patients with progressive intermediate or high -risk CLL were entered into study. A single bolus intravenous infusion of 3Â10 8 -3Â10 9 CD154 -transduced CLL cells was well tolerated without long -term toxicity and without a maximum tolerated dose. The clinical adverse reactions primarily consisted of flu -like symptoms that developed 6 -8 hours after infusion and lasted a few days, and mostly likely were secondary to the induction of endogenous cytokines such as IFNg or IL -12 by CD154 -expressing CLL cells. 149 The infusion of CD154 -transduced leukemia cells led to de novo or increased expression of immune accessory molecules on the overall noninfected CLL cell population in vivo, including CD54, CD85, CD80, and CD86 that were detectable for up to 4 days postinfusion. In addition, there were rising plasma levels of the T H 1 cytokines IL-12 and IFNg at 8-48 hours postinfusion in the majority of patients. An increased number of total circulating T cells and CD4 and CD8 subsets were observed in eight of nine patients analyzed. Up to a 2 -fold increase of leukemia -specific T cells was demonstrated by autologous ELISPOT and mixed lymphocyte reactions in all of three patients tested. The observed clinical responses included significantly reduced leukemia cell counts (>50% at 2 -4 weeks postinfusion ) and up to 90% reduction in lymph node sizes after a single infusion. 149 CD40 transduction apparently restored the lower basal CD40 expression in CLL cells that was sustained for more than 3 months in some *Stage IV renal cell carcinoma ( n = 10 ), head and neck cancer ( four ), cervical cancer ( two ), sarcoma ( two ), rectal carcinoma ( one ), esophageal carcinoma ( one ), breast carcinoma ( one ), peritoneal carcinomatosis ( one ), adenocarcinoma of unknown primary ( one ). Sixty -five percent of these patients have been treated previously with chemotherapy and radiation, 39% with a biologic agent.
Cancer Gene Therapy CD154 treatment of human cancer AW Tong and MJ Stone patient. In addition, reconstituted CD40 -dependent upregulation of CD95 was observed, thereby enabling CLL cells to better stimulate CD154 + T cells and increase the susceptibility of leukemia cells to cytolytic interaction with FasL -expressing T cells. 150 This approach may be mimicked by IL-15, a known T-and NK -cell activator, which also can also enhance CLL CD40 expression. 150 Introduction of CD40 -transduced CLL cells also enhanced antibodydependent cellular cytotoxicity, which augments the activity of antitumor mAb therapy. 151 In a recent pilot study, a patient with plasma cell leukemia ( PCL ) received a cellular vaccine of autologous PCL cells that were previously stimulated with a CD40L transfectant cell line, low-dose IL -2, and autologous, tumor-specific T cells that have been previously sensitized with the CD40 -activated PCL cells. 152 Except for fever and myalgias probably related to IL -2 injections, no other adverse effects were observed. The number of PCL cells in peripheral blood further increased for the first 3 months after T-cell infusion, then decreased below baseline by week 8, and was accompanied by stabilization of serum M protein level. However, the patient did not respond to a second T-cell infusion, at which point T-cell therapy was discontinued. The findings on CLL and PCL suggest that CD154 -transduced or -activated autologous tumor cells may be administered safely, and potentially be of benefit in patients with B -cell hematologic disorders.
The therapeutic applicability of CD154 in epithelial cancers is currently untested. CD154 -transduced tumor cells can potentially serve as an attractive therapeutic option for regionally localized unresectable solid tumors, in view of the potential for mounting a direct growth -inhibitory effect as well as generating protective antitumor immunity. A restricted CD154 expression within the tumor microenvironment can increase its effective concentration for tumor growth inhibition while potentially lowering systemic side effects. The apoptotic sensitizing effect of CD154 on carcinoma cells has been shown to induce an additive response with chemotherapy drugs such as cisplatin, or biologic response modifiers including TNFa, anti -Fas, and ceramide. 54, 68 Thus, CD40 -directed experimental therapy, when administered judiciously, could be applied as an adjuvant to conventional treatment, particularly against drug -resistant tumors such as cisplatin -resistant ovarian carcinomas. 17 Apart from the ex vivo introduction of transfected solid tumor cells, which has been shown to localize in tumor-bearing organs upon reinfusion, selective transfection of tumor cells with the CD154 transgene may be attained with the use of viral vectors with built-in transgene regulatory capability. For example, the CD154 transgene may be delivered by an adenovector under the control of a tissue -specific promoter, such as estrogen response elements that limit expression to estrogen receptor -positive cells in order to generate a direct growth -inhibitory and immunostimulatory effect by breast cancer cells. 153 The enhancer / promoter control of the prostate -specific antigen gene may also be used to rescue transduced DCs from prostate cancerinduced apoptosis. 154 Alternatively, replication-selective adenovectors can be used for transgene delivery, which, by virtue of the design of the transgene-adenovector construct, links transgene expression with restricted viral replication in permissive tumor cells that carry the relevant tumor suppressor gene defect ( p53, Rb mutation, E2F overexpression ). 155 These late -generation, tumor-selective vectors may facilitate the systemic delivery of the CD154 transgene, which in turn can potentiate the oncolytic properties of tumor-selective replicating viruses.
